French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company’s pipeline includes nasal vaccines against zoonotic diseases and parasites such as leishmaniasis and toxoplasmosis, with the majority of Vaxinano’s vaccines intended for use in potential host animals.
According to the Vaxinano website, VXN-LEISH is at the regulatory stage for the treatment of leishmaniasis in dogs, and VXN-COLI is in clinical development for the prevention of E. coli infection in poultry. VXN-TOXO is already in the regulatory stage for the prevention of toxoplasmosis in captive wildlife and in clinical development for use in sheep. In addition, the vaccine against toxoplasmosis is in the proof-of-concept stage for cats and humans.
Vaxinano CEO Jonathan Stauber commented, “This fundraising marks an important milestone for the commercialization of the platform and to prepare for the entry into the clinical phase. The funds raised will allow us to build a world-class management team and develop our promising vaccines, addressing unmet medical needs.” [translated by Google]
Read the Vaxinano press release.
